Results 161 to 170 of about 59,797 (283)

Incidental Resolution of Dopamine Agonist Induced Impulse Control Disorder with GLP‐1 Receptor Agonist

Movement Disorders Clinical Practice, EarlyView.
Hannah Kelly, Thomas Davis
wiley   +1 more source

Challenges of Pain in Parkinson's Disease: Results from the OCEAN Study

Movement Disorders, EarlyView.
Abstract Background Pain is a common non‐motor symptom in Parkinson’s disease (PD) and is often associated to fluctuations. Objective The OpiCapone Effect on motor fluctuations and pAiN (OCEAN) study evaluated the effect of opicapone on fluctuation‐related pain when added to levodopa therapy in PD patients.
Kallol Ray Chaudhuri, Joaquim J. Ferreira, Angelo Antonini, Olivier Rascol, Monica M. Kurtis, Alexander Storch, José‐Francisco Rocha, Raquel Costa, Diogo Magalhães, Guillermo Castilla‐Fernández, Helena C. Brigas, Joerg Holenz, Per Odin, on behalf of the OCEAN study group   +13 more
wiley   +1 more source

Pulmonary Fibrosis in a Patient With a Prolactinoma on Dopamine Agonists: Coincidence or Consequence. [PDF]

JCEM Case Rep
Shah R, Bal A, Arjunan D, Ghosh J, Grossman AB, Dutta P.   +5 more
europepmc   +1 more source

Plasma p‐tau217 Versus p‐tau181 in Parkinson's Disease: Differential Associations with Alzheimer's Disease‐Related Neurostructural Changes and Cognitive Function

Movement Disorders, EarlyView.
Abstract Background Plasma phosphorylated‐tau at threonine‐217 (p‐tau217) and threonine‐181 (p‐tau181) are scalable, minimally invasive biomarkers of Alzheimer's disease (AD) pathology. In Parkinson's disease (PD), AD co‐pathology may contribute to its clinical heterogeneity.
Eleonora Fiorenzato, Simone Cauzzo, Giulia Musso, Roberta Biundo, Chiara Ceolin, Chiara Cosma, Carmelo Alessandro Fogliano, Wassilios G. Meissner, Valentina Misenti, Stefania Moz, Maria Laura Nasi, Francesca Vianello, Renzo Manara, Martina Montagnana, Giuseppe Sergi, Angelo Antonini, on behalf of the OPA Working Group   +16 more
wiley   +1 more source

Inhibitory effects of dopamine agonists on pain-responsive neurons in the central nucleus of the amygdala. [PDF]

J Neurophysiol
Heuermann RJ, Gereau RW.
europepmc   +1 more source

Dopamine Agonist [PDF]

, 2020
openaire   +1 more source

Synthesis of Biased Dopamine Agonists for In Vivo Testing

Dopamine is a neurotransmitter that plays a role in various brain functions, including the regulation of behavior and cognition, voluntary movement, motivation, sleep, mood, attention, working memory, and learning.
Driggers, Julia, Templeton, Andrew
core  

Cholesterol-activated stress granules reduce the membrane localization of DRD2 and promote prolactinoma dopamine agonists resistance. [PDF]

Acta Neuropathol Commun
Peng Y, Yin H, Pei X, Zhang Y, Wang C, Zheng X, Liang H, Yang H, Li S.   +8 more
europepmc   +1 more source

Long-term Outcome of Microscopic Transsphenoidal Surgery for Prolactinomas as an Alternative to Dopamine Agonists. [PDF]

J Korean Med Sci, 2021
Park K, Park KH, Park HR, Lee JM, Kim YH, Kim DY, Won TB, Kong SH, Kim JH, Shin CS, Paek SH.   +10 more
europepmc   +1 more source

Review of nutrition management of pediatric intestinal pseudo‐obstruction

Nutrition in Clinical Practice, EarlyView.
Abstract Chronic intestinal pseudo‐obstruction (CIPO) is a rare, heterogeneous, and debilitating disorder characterized by profound intestinal dysmotility and severe nutrition challenges. Its presentation resembles that of mechanical bowel obstruction, but CIPO occurs in the absence of luminal obstruction.
Senthilkumar Sankararaman, Raisa Rani James, Bushra El‐Amaireh, Andrea Adler, Kadakkal Radhakrishnan, Sujithra Velayuthan   +5 more
wiley   +1 more source